Lymphoma Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

Referring Physician Name:		
Physician Phone: () ext.	Fax: (
Patient Name: SURNAME OHIP Number:		
Telephone: ()		
Date of birth://	_/ Gender: M F Other	
Fax Instructions		
Fax the completed request form, (page 1 and 2), along with the required supporting documentation to the PET Centre of choice for appointment. A complete list of PET Centres and their contact information is available at PET Centre Locations List CCO Health		
☐ BASELINE STAGING PET FOR LYMPH Choose only one: ☐ Hodgkin's Lymphoma ☐ Aggressive Non-Hodgkin's Lympho		
☐ Aggressive Non-Hodgkin's Lymphoma (specify histology):☐ Indolent Lymphoma - where extent of disease will impact patient management		
(e.g., focal radiotherapy)		
Attach the relevant diagnostic imaging repo	orts (CT, US, MRI); and provide images to the PET Centre.	
Physician Signature:	Date:	

Version Date: September 12, 2023

Lymphoma Requisition to PET Centre TO BE COMPLETED BY THE REFERRING PHYSICIAN

Indications: (choose only one)	Patient Name:
INTERIM RESPONSE PET FOR HOL	DGKIN'S LYMPHOMA (ADULTS & PEDIATRICS)
Choose only one:	
2 Chemotherapy Cycles completed	1
☐ 3 Chemotherapy Cycles completed	d .
Date of end of last chemotherapy prior	r to PET:
Attach the pre-treatment CT report; or PET sc	an report if available; and provide images to the PET Centre.
INTERIM RESPONSE PET for NON- (<18 years old; or ≤20 years old and tre	HODGKIN'S LYMPHOMA (PEDIATRICS ONLY) eated at a pediatric centre)
Specify Histology:	
☐ Aggressive Non-Hodgkin's Lymph	oma (specify histology):
Chemotherapy to date: 2 Cycles com	pleted
Date of end of last chemotherapy prior to Pl	ET:
Attach the pre-treatment CT report; or PET scal	n report if available; and provide images to the PET Centre.
- For the evaluation of residual m in patients with Hodgkin's or no therapy (such as radiation or ste	SESSMENT PET (ADULTS & PEDIATRICS) ass(es) or lesion(s) (e.g., bone) following chemotherapy n-Hodgkin's lymphoma when further potentially curative em cell transplantation) is being considered; OR antigen receptor (CAR) T-cell therapy, ninety (90) days
Complete Sections A), B), and C)	
A) Residual Mass(es) or Lesion(s); Ol	<u>R</u>
☐ Ninety (90) days following CAR T-c	cell therapy
B) Hodgkin's; OR	
C) Date of end of last therapy prior to PE	T:
	or correlation with PET and provide images to the PET Centre.
Physician Signature:	Date:

Version Date: September 12, 2023